Ahr and Osteoporosis
Ahr 和骨质疏松症
基本信息
- 批准号:8785839
- 负责人:
- 金额:$ 67.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AHR geneAgonistAromatic Polycyclic HydrocarbonsAryl Hydrocarbon ReceptorBenzo(a)pyreneBiological AssayBone Marrow CellsBone ResorptionCREB1 geneCell NucleusCellsChemicalsChronicCigaretteCigarette SmokerClinicalCytochrome P450DataDioxinsEnzymesEventExcisionF2-IsoprostanesFractureGene ExpressionGenesHealthHydrogen PeroxideHypoxiaJointsKnock-in MouseLocationMarrowMediatingMediator of activation proteinMetabolicMicrosomesMitochondriaMolecularMusOsteoblastsOsteoclastsOsteocytesOsteogenesisOsteoporosisOxidative StressPathway interactionsPhenotypePlayPolychlorinated BiphenylsProductionProteinsReactive Oxygen SpeciesReceptor ActivationReporterRiskRoleSignal TransductionSkeletonSmall Interfering RNASmokeSmokerStressTestingTetrachlorodibenzodioxinToxinbasebonebone cellbone lossbone masscalcineurin phosphatasecell typecigarette smokingcigarette smokingcytokinedentin matrix protein 1high riskinhibitor/antagonistinnovationmouse Ahr proteinmouse modelmultidisciplinarymutantosteoclastogenesisoxidative damagepromoterresponseskeletaltherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Cigarette smokers suffer from severe osteoporosis, and are therefore at an exceptionally high risk of skeletal fracture. However, the mechanism through which smoke causes bone loss remains unclear. We find that BaP (benzo[a]pyrene) and TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), two of over 200 known chemicals found in cigarette smoke, trigger the aryl hydrocarbon receptor (Ahr) and the cytochrome P450 (Cyp1) enzymes to stimulate bone removal. Despite these observations, several gaps in our understanding remain. First, we are uncertain which bone cell, osteoclast, osteoblast or osteocyte, primarily mediates this action. Therefore, in Specific Aim 1, we will study the bone phenotype of mice in which the Ahr gene is deleted selectively in each cell type, and then examine the effect of the Ahr agonists BaP and TCDD on skeletal mass and remodeling. Second, we are unclear whether the osteoclast-stimulatory action of Ahr agonists involves the activation of mitochondrial or microsomal Cyp1s, and whether the reactive oxygen species (ROS) so produced mediate this action. Therefore, in Specific Aim 2, we will administer BaP and/or TCDD to knock-in mice expressing Cyp1 proteins either in mitochondria or in microsomes. We will phenotype their skeletons and study ROS production in isolated bone marrow cells. Our previous studies have further shown that ROS activate mitochondria-to-nucleus signals to generate a pro-osteoclastogenic footprint comprising CREB, C/EBPδ, NF-κB, NFAT2, and hnRNPA2. In Specific Aim 3, we will determine whether this transcriptional footprint is activated by Ahr agonists. If so, we will utilize siRNA and/or chemical inhibitors to validate the role of each molecule, as well as promoter-reporter assays and ChIP to confirm that the footprint transactivates osteoclast gene expression. These studies should establish the Ahr as a therapeutic target for osteoporosis and unravel, at least to an extent, the molecular basis underlying the osteoporosis noted in smokers.
描述(由申请人提供):吸烟者患有严重的骨质疏松症,因此骨骼骨折的风险极高。然而,吸烟导致骨质流失的机制仍不清楚。我们发现BaP(苯并[a]芘)和TCDD(2,3,7,8-四氯二苯并-p-二恶英),香烟烟雾中发现的200多种已知化学物质中的两种,触发芳烃受体(Ahr)和细胞色素P450(Cyp 1)酶,刺激骨去除。尽管有这些意见,我们的理解仍然存在一些差距。首先,我们不确定哪种骨细胞,破骨细胞,成骨细胞或骨细胞,主要介导这一行动。因此,在特定目标1中,我们将研究在每种细胞类型中选择性删除Ahr基因的小鼠的骨表型,然后检查Ahr激动剂BaP和TCDD对骨骼质量和重塑的影响。其次,我们不清楚Ahr激动剂的破骨细胞刺激作用是否涉及线粒体或微粒体Cyp 1的激活,以及如此产生的活性氧(ROS)是否介导了这一作用。因此,在具体目标2中,我们将给予BaP和/或TCDD基因敲入小鼠,在线粒体或微粒体中表达Cyp 1蛋白。我们将对它们的骨骼进行表型分析,并研究离体骨髓细胞中ROS的产生。我们以前的研究进一步表明,ROS激活骨细胞到细胞核的信号,产生包括CREB、C/EBPδ、NF-κB、NFAT 2和hnRNPA 2的促破骨细胞生成足迹。在特定目标3中,我们将确定这种转录足迹是否被Ahr激动剂激活。如果是这样,我们将利用siRNA和/或化学抑制剂来验证每个分子的作用,以及启动子-报告基因测定和ChIP来确认足迹反式激活破骨细胞基因表达。这些研究应确立Ahr作为骨质疏松症的治疗靶点,并至少在一定程度上揭示吸烟者骨质疏松症的分子基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NARAYAN G AVADHANI其他文献
NARAYAN G AVADHANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NARAYAN G AVADHANI', 18)}}的其他基金
CYP2E1 Mediated Mitochondrial Injury and Cell Damage in Alcohol Liver Disease
CYP2E1 介导的酒精性肝病中的线粒体损伤和细胞损伤
- 批准号:
9404927 - 财政年份:2015
- 资助金额:
$ 67.21万 - 项目类别:
CYP2E1 Mediated Mitochondrial Injury and Cell Damage in Alcohol Liver Disease
CYP2E1 介导的酒精性肝病中的线粒体损伤和细胞损伤
- 批准号:
9003017 - 财政年份:2015
- 资助金额:
$ 67.21万 - 项目类别:
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue Injury
线粒体靶向 CYP2E1 和 HO-1 在酒精介导的组织损伤中的作用
- 批准号:
8135177 - 财政年份:2010
- 资助金额:
$ 67.21万 - 项目类别:
Mechanisms and Functions of Bimodally Targeted Cytochrome P450s to Mitochondria
双峰靶向细胞色素 P450 线粒体的机制和功能
- 批准号:
7934368 - 财政年份:2009
- 资助金额:
$ 67.21万 - 项目类别:
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue Injury
线粒体靶向 CYP2E1 和 HO-1 在酒精介导的组织损伤中的作用
- 批准号:
7522660 - 财政年份:2008
- 资助金额:
$ 67.21万 - 项目类别:
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue Injury
线粒体靶向 CYP2E1 和 HO-1 在酒精介导的组织损伤中的作用
- 批准号:
8119383 - 财政年份:2008
- 资助金额:
$ 67.21万 - 项目类别:
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue Injury
线粒体靶向 CYP2E1 和 HO-1 在酒精介导的组织损伤中的作用
- 批准号:
8306359 - 财政年份:2008
- 资助金额:
$ 67.21万 - 项目类别:
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue Injury
线粒体靶向 CYP2E1 和 HO-1 在酒精介导的组织损伤中的作用
- 批准号:
7900513 - 财政年份:2008
- 资助金额:
$ 67.21万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 67.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 67.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 67.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




